Scaling up cervical cancer screening coverage in the U.S. to 90 percent could expedite elimination of the disease and avert more than 1,000 additional cases per year, according to a new study led by researchers from Harvard T.H. Chan School of Public Health. Their modeling study found that this would be the most effective way to speed up elimination, compared to current levels of screening and human papillomavirus (HPV) vaccination.
“Although HPV vaccination will be a major contributor to reducing cervical cancer over time, we found that in the immediate term, screening continues to play a critical role in reducing the burden of cervical cancer in U.S.,” said Dr. Emily Burger, a research scientist in the Center for Health Decision Science at Harvard Chan School who co-led the study.
The study was published online in The Lancet Public Health on February 10.
This analysis is an extension of two studies published last week evaluating the potential for and timing of cervical cancer elimination, as well as the mortality impacts of scaling up human papillomavirus (HPV) vaccination, cervical cancer screening, and cancer treatment services in 78 low-income and lower-middle income countries. Those analyses, published in The Lancet, were co-led by three modeling groups comprising the World Health Organization (WHO) Cervical Cancer Elimination Modeling Consortium (CCEMC), which includes the authors of the current study.Tags: Friday Letter Submission, Publish on February 14